Clinical trial
A Study Of Rosiglitazone Plus Insulin To Treat Type 2 Diabetes Mellitus Patients
NCT00349427 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00349427 |
|---|---|
| Title | A Study Of Rosiglitazone Plus Insulin To Treat Type 2 Diabetes Mellitus Patients |
| Official title | A Randomized, Double-Blind, Placebo-Control, Clinical Evaluation of Insulin Plus Rosiglitazone Compared to Insulin Plus Placebo for 24 Weeks in Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | Rosiglitazone 4 mg |
| Enrollment | 256 |
| Start date | Oct 1, 2005 |
| First posted | Jul 7, 2006 |
| Last update posted | Jun 4, 2012 |
| Countries | China |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: